Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: R-CHOP | Statement: [Rituxan, combinationRegimen, R-CHOP]

Target entity: R-CHOP
Context triple: [Rituxan, combinationRegimen, R-CHOP]

• A. Alimta
  Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
• B. Rituxan
  Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
• C. Xeloda
  Xeloda is an oral chemotherapy drug (capecitabine) commonly used to treat various cancers, including colorectal and breast cancer.
• D. Imbruvica
  Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
• E. bortezomib
  Bortezomib is a proteasome inhibitor chemotherapy drug primarily used in the treatment of multiple myeloma and certain types of lymphoma.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"

Entity: R-CHOP
Triple: [Rituxan, combinationRegimen, R-CHOP]

R-CHOP is a standard chemotherapy regimen combining rituximab with multiple cytotoxic drugs, commonly used to treat non-Hodgkin lymphoma.

Target entity: R-CHOP
Target entity description: R-CHOP is a standard chemotherapy regimen combining rituximab with multiple cytotoxic drugs, commonly used to treat non-Hodgkin lymphoma.

• A. Alimta
  Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
• B. Rituxan
  Rituxan is a monoclonal antibody drug (rituximab) widely used to treat certain blood cancers and autoimmune diseases by targeting the CD20 protein on B cells.
• C. Xeloda
  Xeloda is an oral chemotherapy drug (capecitabine) commonly used to treat various cancers, including colorectal and breast cancer.
• D. Imbruvica
  Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
• E. bortezomib
  Bortezomib is a proteasome inhibitor chemotherapy drug primarily used in the treatment of multiple myeloma and certain types of lymphoma.
• F. None of above. chosen

Target predicate: combinationRegimen
Context triple: [Rituxan, combinationRegimen, R-CHOP]

• A. doseRegimen
  Indicates the specific schedule, frequency, and amount with which a dose of a substance or medication is to be administered.
• B. hasDosingRegimen
  Indicates that an entity is associated with a specific dosing regimen, defining how and when a dose is to be administered.
• C. administeredAlongside chosen
  Indicates that one treatment, drug, or intervention is given or applied at the same time as another.
• D. isProdrugOf
  Indicates that one substance is a precursor form that is metabolized in the body to produce the active form of another substance.
• E. hasLoadingDoseRegimen
  Indicates that an entity is associated with a specific initial (loading) dosing regimen administered to rapidly achieve a desired therapeutic level.
• F. None of above.